Immune responses in parkinson's disease: Interplay between central and peripheral immune systems

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Su, Xiaomin ^a   Federoff, Howard J ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NERVE DEGENERATION; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; REVIEW; RISK FACTOR; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY;

HUMANS; IMMUNE SYSTEM; INFLAMMATION; PARKINSON DISEASE;

EID: 84900017196     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/275178     Document Type: Review

References (128)

1. Litvan I., Bhatia K. P., Burn D. J., Goetz C. G., Lang A. E., McKeith I., Quinn N., Sethi K. D., Shults C., Wenning G. K., SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Movement Disorders 2003 18 5 467 486 2-s2.0-0038147327 10.1002/mds.10459
2. Dickson D. W., Fujishiro H., Orr C., DelleDonne A., Josephs K. A., Frigerio R., Burnett M., Parisi J. E., Klos K. J., Ahlskog J. E., Neuropathology of non-motor features of Parkinson disease. Parkinsonism and Related Disorders 2009 15 3 S1 S5 2-s2.0-71849089219 10.1016/S1353-8020(09)70769-2
3. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models. Neuron 2003 39 6 889 909 2-s2.0-0141741347 10.1016/S0896-6273(03)00568-3
4. Kamer A. R., Craig R. G., Dasanayake A. P., Brys M., Glodzik-Sobanska L., de Leon M. J., Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimer's and Dementia 2008 4 4 242 250 2-s2.0-45749107101 10.1016/j.jalz.2007.08.004
5. Popescu B. O., Toescu E. C., Popescu L. M., Bajenaru O., Muresanu D. F., Schultzberg M., Bogdanovic N., Blood-brain barrier alterations in ageing and dementia. Journal of the Neurological Sciences 2009 283 1-2 99 106 2-s2.0-67349220310 10.1016/j.jns.2009.02.321
6. Evans M. C., Couch Y., Sibson N., Turner M. R., Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences 2013 53 34 41
7. Sanchez-Lopez F., Tasset I., Aguera E., Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease. Neurological Research 2012 34 7 721 724
8. Hsiao H. Y., Chen Y. C., Chen H. M., Tu P. H., Chern Y., A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Human Molecular Genetics 2013 22 9 1826 1842
9. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 2-s2.0-0023789193
10. Blum-Degena D., Müller T., Kuhn W., Gerlach M., Przuntek H., Riederer P., Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letters 1995 202 1-2 17 20 2-s2.0-0029417080 10.1016/0304-3940(95) 12192-7
11. Mogi M., Harada M., Kondob T., Riederer P., Inagaki H., Minami M., Nagatsu T., Interleukin-1 β interleukin-6, epidermal growth factor and transforming growth factor- α are elevated in the brain from parkinsonian patients. Neuroscience Letters 1994 180 2 147 150 2-s2.0-0028171374 10.1016/0304-3940(94)90508-8
12. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T., Tumor necrosis factor- α (TNF- α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neuroscience Letters 1994 165 1-2 208 210 2-s2.0-0028178281 10.1016/0304-3940(94)90746-3
13. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T., Interleukin (IL)-1 β IL-2, IL-4, IL-6 and transforming growth factor- α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neuroscience Letters 1996 211 1 13 16 2-s2.0-0030582991 10.1016/0304-3940(96)12706-3
14. Reale M., Iarlori C., Thomas A., Gambi D., Perfetti B., Di Nicola M., Onofrj M., Peripheral cytokines profile in Parkinson's disease. Brain, Behavior, and Immunity 2009 23 1 55 63 2-s2.0-56849086964 10.1016/j.bbi.2008.07.003
15. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R. B., Brooks D. J., In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 2006 21 2 404 412 2-s2.0-30744472146 10.1016/j.nbd.2005.08.002
16. Su X., Maguire-Zeiss K. A., Giuliano R., Prifti L., Venkatesh K., Federoff H. J., Synuclein activates microglia in a model of Parkinson's disease. Neurobiology of Aging 2008 29 11 1690 1701 2-s2.0-51449099473 10.1016/j.neurobiolaging.2007.04.006
17. Su X., Federoff H. J., Maguire-Zeiss K. A., Mutant α -synuclein overexpression mediates early proinflammatory activity. Neurotoxicity Research 2009 16 3 238 254 2-s2.0-70349917814 10.1007/s12640-009-9053-x
18. Castaño A., Herrera A. J., Cano J., Machado A., Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. Journal of Neurochemistry 1998 70 4 1584 1592 2-s2.0-0031881687
19. Hunot S., Boissière F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E. C., Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996 72 2 355 363 2-s2.0-0343844458 10.1016/0306-4522(95)00578-1
20. Hirsch E. C., Hunot S., Damier P., Faucheux B., Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Annals of Neurology 1998 44 3 S115 S120 2-s2.0-0031715925
21. Nagatsu T., Mogi M., Ichinose H., Togari A., Cytokines in Parkinson's disease. Journal of Neural Transmission 2000 58 143 151 2-s2.0-0033694060
22. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T., Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. Journal of Neural Transmission 2000 107 3 335 341 2-s2.0-0034023082
23. Hailer N. P., Vogt C., Korf H.-W., Dehghani F., Interleukin-1 β exacerbates and interleukin-1 receptor antagonist attenuates neuronal injury and microglial activation after excitotoxic damage in organotypic hippocampal slice cultures. European Journal of Neuroscience 2005 21 9 2347 2360 2-s2.0-20444441180 10.1111/j.1460-9568.2005.04067.x
24. Li C., Zienkiewicz J., Hawiger J., Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1 β signaling pathway. Journal of Biological Chemistry 2005 280 28 26152 26159 2-s2.0-22544484235 10.1074/jbc.M503262200
25. Hartmann A., Hunot S., Hirsch E. C., Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Experimental Neurology 2003 184 2 561 564 2-s2.0-0842277733 10.1016/j.expneurol.2003.08.004
26. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debré P., Agid Y., Dugas B., Hirsch E. C., Fc ε RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor- α in glial cells. Journal of Neuroscience 1999 19 9 3440 3447 2-s2.0-0033121299
27. Dawson V. L., Dawson T. M., Bartley D. A., Uhl G. R., Snyder S. H., Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. Journal of Neuroscience 1993 13 6 2651 2661 2-s2.0-0027178135
28. Hunot S., Flavell R. A., Death of a monopoly? Science 2001 292 5518 865 866 2-s2.0-0035805523 10.1126/science.1060885
29. Gao H.-M., Liu B., Zhang W., Hong J.-S., Novel anti-inflammatory therapy for Parkinson's disease. Trends in Pharmacological Sciences 2003 24 8 395 401 2-s2.0-0043162103 10.1016/S0165-6147(03)00176-7
30. Li Z., Jansen M., Ogburn K., Salvatierra L., Hunter L., Mathew S., Figueiredo-Pereira M. E., Neurotoxic prostaglandin J2 enhances cyclooxygenase-2 expression in neuronal cells through the p38MAPK pathway: a death wish? Journal of Neuroscience Research 2004 78 6 824 836 2-s2.0-10644230914 10.1002/jnr.20346
31. Harris S. G., Padilla J., Koumas L., Ray D., Phipps R. P., Prostaglandins as modulators of immunity. Trends in Immunology 2002 23 3 144 150 2-s2.0-0036499224 10.1016/S1471-4906(01)02154-8
32. Jackson-Lewis V., Smeyne R. J., MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotoxicity Research 2005 7 3 193 201 2-s2.0-21744440118 10.1007/BF03036449
33. Block M. L., Zecca L., Hong J.-S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038
34. Perry V. H., Matyszak M. K., Fearn S., Altered antigen expression of microglia in the aged rodent CNS. Glia 1993 7 1 60 67 2-s2.0-0027352040
35. Sheffield L. G., Berman N. E. J., Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiology of Aging 1998 19 1 47 55 2-s2.0-0031960498 10.1016/S0197-4580(97)00168-1
36. Frank M. G., Barrientos R. M., Biedenkapp J. C., Rudy J. W., Watkins L. R., Maier S. F., mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiology of Aging 2006 27 5 717 722 2-s2.0-33646006075 10.1016/j.neurobiolaging.2005.03.013
37. Godbout J. P., Chen J., Abraham J., Richwine A. F., Berg B. M., Kelley K. W., Johnson R. W., Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. The FASEB Journal 2005 19 10 1329 1331 2-s2.0-23444443814 10.1096/fj.05-3776fje
38. Wong A. M., Patel N. V., Patel N. K., Wei M., Morgan T. E., De Beer M. C., De Villiers W. J. S., Finch C. E., Macrosialin increases during normal brain aging are attenuated by caloric restriction. Neuroscience Letters 2005 390 2 76 80 2-s2.0-26244433532 10.1016/j.neulet.2005.07.058
39. Stichel C. C., Luebbert H., Inflammatory processes in the aging mouse brain: participation of dendritic cells and T-cells. Neurobiology of Aging 2007 28 10 1507 1521 2-s2.0-34547749000 10.1016/j.neurobiolaging.2006.07.022
40. Letiembre M., Hao W., Liu Y., Walter S., Mihaljevic I., Rivest S., Hartmann T., Fassbender K., Innate immune receptor expression in normal brain aging. Neuroscience 2007 146 1 248 254 2-s2.0-34247471687 10.1016/j. neuroscience.2007.01.004
41. Griffin R., Nally R., Nolan Y., McCartney Y., Linden J., Lynch M. A., The age-related attenuation in long-term potentiation is associated with microglial activation. Journal of Neurochemistry 2006 99 4 1263 1272 2-s2.0-33750480549 10.1111/j.1471-4159.2006.04165.x
42. Njie E. G., Boelen E., Stassen F. R., Steinbusch H. W. M., Borchelt D. R., Streit W. J., Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiology of Aging 2012 33 1 195.e1 195.e12 2-s2.0-81355132325 10.1016/j.neurobiolaging.2010.05.008
43. Chen J., Buchanan J. B., Sparkman N. L., Godbout J. P., Freund G. G., Johnson R. W., Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain, Behavior, and Immunity 2008 22 3 301 311 2-s2.0-38649119160 10.1016/j.bbi.2007.08.014
44. Maher F. O., Clarke R. M., Kelly A., Nally R. E., Lynch M. A., Interaction between interferon γ and insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation. Journal of Neurochemistry 2006 96 6 1560 1571 2-s2.0-33644788171 10.1111/j.1471-4159.2006.03664.x
45. Chao C. C., Hu S., Peterson P. K., Modulation of human microglial cell superoxide production by cytokines. Journal of Leukocyte Biology 1995 58 1 65 70 2-s2.0-0029087348
46. Davila D. R., Edwards C. K. III, Arkins S., Simon J., Kelley K. W., Interferon- γ -induced priming for secretion of superoxide anion and tumor necrosis factor- α declines in macrophages from aged rats. The FASEB Journal 1990 4 11 2906 2911 2-s2.0-0025244176
47. Maher F. O., Nolan Y., Lynch M. A., Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat. Neurobiology of Aging 2005 26 5 717 728 2-s2.0-13644253039 10.1016/j. neurobiolaging.2004.07.002
48. Ye S.-M., Johnson R. W., An age-related decline in interleukin-10 may contribute to the increased expression of interleukin-6 in brain of aged mice. NeuroImmunoModulation 2001 9 4 183 192 2-s2.0-0035720799 10.1159/000049025
49. Nichols N. R., Day J. R., Laping N. J., Johnson S. A., Finch C. E., GFAP mRNA increases with age in rat and human brain. Neurobiology of Aging 1993 14 5 421 429 2-s2.0-0027169639 10.1016/0197-4580(93)90100-P
50. Cotrina M. L., Nedergaard M., Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. Journal of Neuroscience Research 2002 67 1 21 29 2-s2.0-0036144231 10.1002/jnr.10107
51. Porchet R., Probst A., Bouras C., Dráberová E., Dráber P., Riederer B. M., Analysis of gial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics 2003 3 8 1476 1485 2-s2.0-0042360512 10.1002/pmic.200300456
52. Pekny M., Pekna M., Astrocyte intermediate filaments in CNS pathologies and regeneration. Journal of Pathology 2004 204 4 428 437 2-s2.0-7944223409 10.1002/path.1645
53. Tichauer J., Saud K., von Bernhardi R., Modulation by astrocytes of microglial cell-mediated neuroinflammation: effect on the activation of microglial signaling pathways. NeuroImmunoModulation 2007 14 3-4 168 174 2-s2.0-37049017788 10.1159/000110642
54. Abbott N. J., Rönnbäck L., Hansson E., Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience 2006 7 1 41 53 2-s2.0-29244463365 10.1038/nrn1824
55. Zlokovic B. V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008 57 2 178 201 2-s2.0-38149090292 10.1016/j.neuron.2008.01.003
56. Weiss J. M., Berman J. W., Astrocyte expression of monocyte chemoattractant protein-1 is differentially regulated by transforming growth factor beta. Journal of Neuroimmunology 1998 91 1-2 190 197 2-s2.0-0032476641 10.1016/S0165-5728(98)00183-0
57. Couch Y., Alvarez-Erviti L., Sibson N. R., Wood M. J. A., Anthony D. C., The acute inflammatory response to intranigral α -synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. Journal of Neuroinflammation 2011 8, article 166 2-s2.0-82155168545 10.1186/1742-2094-8-166
58. Reynolds A. D., Stone D. K., Mosley R. L., Gendelman H. E., Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. Journal of Proteome Research 2009 8 7 3497 3511 2-s2.0-67650351515 10.1021/pr9001614
59. Reynolds A. D., Stone D. K., Mosley R. L., Gendelman H. E., Nitrated α -synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. Journal of Immunology 2009 182 7 4137 4149 2-s2.0-64249169415 10.4049/jimmunol.0803982
60. Sulzer D., Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends in Neurosciences 2007 30 5 244 250 2-s2.0-34247631275 10.1016/j.tins.2007.03.009
61. Lee H.-J., Patel S., Lee S.-J., Intravesicular localization and exocytosis of α -synuclein and its aggregates. Journal of Neuroscience 2005 25 25 6016 6024 2-s2.0-21344456506 10.1523/JNEUROSCI.0692-05.2005
62. Jin J., Shie F.-S., Liu J., Wang Y., Davis J., Schantz A. M., Montine K. S., Montine T. J., Zhang J., Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α -synuclein. Journal of Neuroinflammation 2007 4, article 2 2-s2.0-33846668868 10.1186/1742-2094-4-2
63. Maekawa T., Kubo M., Yokoyama I., Ohta E., Obata F., Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochemical and Biophysical Research Communications 2010 392 3 431 435 2-s2.0-76349085159 10.1016/j.bbrc.2010.01.041
64. Miklossy J., Arai T., Guo J.-P., Klegeris A., Yu S., McGeer E. G., McGeer P. L., LRRK2 expression in normal and pathologic human brain and in human cell lines. Journal of Neuropathology and Experimental Neurology 2006 65 10 953 963 2-s2.0-33749463769 10.1097/01.jnen.0000235121.98052.54
65. Gillardon F., Schmid R., Draheim H., Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012 208 41 48 2-s2.0-84858620880 10.1016/j.neuroscience.2012.02. 001
66. Lopez de Maturana R., Aguila J. C., Sousa A., Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease. Neurobiology of Aging 2014 35 5 1116 1124
67. Marker D. F., Puccini J. M., Mockus T. E., Barbieri J., Lu S. M., Gelbard H. A., LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. Journal of Neuroinflammation 2012 9, article 261
68. Kim B., Yang M.-S., Choi D., Kim J.-H., Kim H.-S., Seol W., Choi S., Jou I., Kim E.-Y., Joe E.-H., Impaired inflammatory responses in murine lrrk2-knockdown brain microglia. PLoS ONE 2012 7 4 2-s2.0-84859499649 10.1371/journal.pone.0034693 e34693
69. Shimura H., Hattori N., Kubo S.-I., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T., Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics 2000 25 3 302 305 2-s2.0-0033933048 10.1038/77060
70. Frank-Cannon T. C., Tran T., Ruhn K. A., Martinez T. N., Hong J., Marvin M., Hartley M., Treviño I., O'Brien D. E., Casey B., Goldberg M. S., Tansey M. G., Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. Journal of Neuroscience 2008 28 43 10825 10834 2-s2.0-58149149970 10.1523/JNEUROSCI.3001-08.2008
71. Zheng B., Liao Z., Locascio J. J., PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Science Translational Medicine 2010 2 52 52ra73
72. St-Pierre J., Drori S., Uldry M., Silvaggi J. M., Rhee J., Jäger S., Handschin C., Zheng K., Lin J., Yang W., Simon D. K., Bachoo R., Spiegelman B. M., Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006 127 2 397 408 2-s2.0-33749999530 10.1016/j.cell.2006.09.024
73. Mudò G., Mäkelä J., Di Liberto V., Tselykh T. V., Olivieri M., Piepponen P., Eriksson O., Mälkiä A., Bonomo A., Kairisalo M., Aguirre J. A., Korhonen L., Belluardo N., Lindholm D., Transgenic expression and activation of PGC-1 α protect dopaminergic neurons in the MPTP mouse model of Parkinsons disease. Cellular and Molecular Life Sciences 2012 69 7 1153 1165 2-s2.0-84859159081 10.1007/s00018-011-0850-z
74. Sczelecki S., Besse-Patin A., Abboud A., Loss of Pgc-1alpha expression in aging mouse muscle potentiates glucose intolerance and systemic inflammation. The American Journal of Physiology Endocrinology and Metabolism 2014 306 2 E157 E167
75. Scalzo P., Kümmer A., Cardoso F., Teixeira A. L., Increased serum levels of soluble tumor necrosis factor- α receptor-1 in patients with Parkinson's disease. Journal of Neuroimmunology 2009 216 1-2 122 125 2-s2.0-71749083139 10.1016/j.jneuroim.2009.08.001
76. Dufek M., Hamanová M., Lokaj J., Goldemund D., Rektorová I., Michálková Z., Sheardová K., Rektor I., Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism and Related Disorders 2009 15 4 318 320 2-s2.0-64249101537 10.1016/j.parkreldis.2008.05.014
77. Chen H., O'Reilly E. J., Schwarzschild M. A., Ascherio A., Peripheral inflammatory biomarkers and risk of Parkinson's disease. The American Journal of Epidemiology 2008 167 1 90 95 2-s2.0-37549057265 10.1093/aje/kwm260
78. Devos D., Lebouvier T., Lardeux B., Colonic inflammation in Parkinson's disease. Neurobiology of Disease 2013 50 42 48
79. Przuntek H., Müller T., Riederer P., Diagnostic staging of Parkinson's disease: conceptual aspects. Journal of Neural Transmission 2004 111 2 201 216 2-s2.0-10744223160 10.1007/s00702-003-0102-y
80. Weller C., Oxlade N., Dobbs S. M., Dobbs R. J., Charlett A., Bjarnason I. T., Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunology and Medical Microbiology 2005 44 2 129 135 2-s2.0-24344442953 10.1016/j.femsim.2005.01.011
81. Hasegawa Y., Inagaki T., Sawada M., Suzumura A., Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurologica Scandinavica 2000 101 3 159 164 2-s2.0-0034005171 10.1034/j.1600-0404.2000.101003159.x
82. Beyer M. K., Herlofson K., Arsland D., Larsen J. P., Causes of death in a community-based study of Parkinson's disease. Acta Neurologica Scandinavica 2001 103 1 7 11
83. D'Amelio M., Ragonese P., Morgante L., Reggio A., Callari G., Salemi G., Savettieri G., Long-term survival of Parkinson's disease: a population-based study. Journal of Neurology 2006 253 1 33 37 2-s2.0-31544482391 10.1007/s00415-005-0916-7
84. Arai H., Furuya T., Mizuno Y., Mochizuki H., Inflammation and infection in Parkinson's disease. Histology and Histopathology 2006 21 4-6 673 678 2-s2.0-33645559991
85. Brochard V., Combadière B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.-M., Duyckaerts C., Flavell R. A., Hirsch E. C., Hunot S., Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. Journal of Clinical Investigation 2009 119 1 182 192 2-s2.0-58849107919 10.1172/JCI36470
86. Stone D. K., Reynolds A. D., Mosley R. L., Gendelman H. E., Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxidants and Redox Signaling 2009 11 9 2151 2166 2-s2.0-68249145501 10.1089/ars.2009.2460
87. Kortekaas R., Leenders K. L., van Oostrom J. C. H., Vaalburg W., Bart J., Willemsen A. T. M., Hendrikse N. H., Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology 2005 57 2 176 179 2-s2.0-13144255682 10.1002/ana.20369
88. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
89. Carvey P. M., Chang Q., Lipton J. W., Ling Z., Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Frontiers in Bioscience 2003 8 s826 s837 2-s2.0-4344691112
90. Ling Z., Gayle D. A., Ma S. Y., Lipton J. W., Tong C. W., Hong J.-S., Carvey P. M., In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Movement Disorders 2002 17 1 116 124 2-s2.0-0036460861 10.1002/mds.10078
91. Ling Z., Chang Q. A., Tong C. W., Leurgans S. E., Lipton J. W., Carvey P. M., Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Experimental Neurology 2004 190 2 373 383 2-s2.0-8644287610 10.1016/j.expneurol.2004.08.006
92. Engler H., Doenlen R., Riether C., Engler A., Niemi M.-B., Besedovsky H. O., Rey A. D., Pacheco-López G., Feldon J., Schedlowski M., Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Brain, Behavior, and Immunity 2009 23 4 518 526 2-s2.0-63249120288 10.1016/j.bbi.2009.01.018
93. Villarán R. F., Espinosa-Oliva A. M., Sarmiento M., De Pablos R. M., Argüelles S., Delgado-Cortés M. J., Sobrino V., Van Rooijen N., Venero J. L., Herrera A. J., Cano J., MacHado A., Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. Journal of Neurochemistry 2010 114 6 1687 1700 2-s2.0-77956321331 10.1111/j.1471-4159.2010.06879.x
94. Hawkes C. H., Del Tredici K., Braak H., A timeline for Parkinson's disease. Parkinsonism and Related Disorders 2010 16 2 79 84 2-s2.0-75749135592 10.1016/j.parkreldis.2009.08.007
95. Menza M., Dobkin R. D., Marin H., Mark M. H., Gara M., Bienfait K., Dicke A., Kusnekov A., The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics 2010 51 6 474 479 2-s2.0-78649686234 10.1176/appi.psy.51.6.474
96. Blaser M. J., Who are we? Indigenous microbes and the ecology of human diseases. EMBO Reports 2006 7 10 956 960 2-s2.0-33749241734 10.1038/sj.embor. 7400812
97. Nielsen H. H., Qiu J., Friis S., Wermuth L., Ritz B., Treatment for Helicobacter pylori infection and risk of parkinson's disease in Denmark. European Journal of Neurology 2012 19 6 864 869 2-s2.0-84855764812 10.1111/j.1468-1331.2011.03643.x
98. Bjarnason I. T., Charlett A., Dobbs R. J., Dobbs S. M., Ibrahim M. A. A., Kerwin R. W., Mahler R. F., Oxlade N. L., Peterson D. W., Plant J. M., Price A. B., Weller C., Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic Parkinsonism. Part 2: response of facets of clinical idiopathic Parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study. Helicobacter 2005 10 557 287 2-s2.0-25444515150 10.1111/j.1523-5378.2005.00354.x
99. Savica R., Carlin J. M., Grossardt B. R., Bower J. H., Ahlskog J. E., Maraganore D. M., Bharucha A. E., Rocca W. A., Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009 73 21 1752 1758 2-s2.0-73349092154 10.1212/WNL.0b013e3181c34af5
100. Arvanitakis Z., Wilson R. S., Schneider J. A., Bienias J. L., Evans D. A., Bennett D. A., Diabetes mellitus and progression of rigidity and gait disturbance in older persons. Neurology 2004 63 6 996 1001 2-s2.0-4644313269
101. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 7 1793 1801 2-s2.0-33745861300 10.1172/JCI29069
102. Berg A. H., Scherer P. E., Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005 96 9 939 949 2-s2.0-19044393872 10.1161/01.RES.0000163635.62927.34
103. Zoccali C., Tripepi G., Cambareri F., Catalano F., Finocchiaro P., Cutrupi S., Pizzini P., Testa A., Spoto B., Panuccio V., Enia G., Mallamaci F., Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. Journal of Renal Nutrition 2005 15 1 125 130 2-s2.0-19944426037 10.1053/j.jrn.2004.09.036
104. Cai D., Yuan M., Frantz D. F., Melendez P. A., Hansen L., Lee J., Shoelson S. E., Local and systemic insulin resistance resulting from hepatic activation of IKK- β and NF- B. Nature Medicine 2005 11 2 183 190 2-s2.0-14644427890 10.1038/nm1166
105. Ehses J. A., Perren A., Eppler E., Ribaux P., Pospisilik J. A., Maor-Cahn R., Gueripel X., Ellingsgaard H., Schneider M. K. J., Biollaz G., Fontana A., Reinecke M., Homo-Delarche F., Donath M. Y., Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007 56 9 2356 2370 2-s2.0-34548431826 10.2337/db06-1650
106. De Souza C. T., Araujo E. P., Bordin S., Ashimine R., Zollner R. L., Boschero A. C., Saad M. J. A., Velloso L. A., Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 2005 146 10 4192 4199 2-s2.0-24944438230 10.1210/en.2004-1520
107. Saghizadeh M., Ong J. M., Garvey W. T., Henry R. R., Kern P. A., The expression of TNF α by human muscle: relationship to insulin resistance. Journal of Clinical Investigation 1996 97 4 1111 1116 2-s2.0-0030028606
108. Barnum C. J., Tansey M. G., Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease? Current Neurology and Neuroscience Reports 2012 12 4 350 358
109. Stolp H. B., Dziegielewska K. M., Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathology and Applied Neurobiology 2009 35 2 132 146 2-s2.0-61849149792 10.1111/j.1365-2990.2008.01005.x
110. Tracey K. J., The inflammatory reflex. Nature 2002 420 6917 853 859 2-s2.0-0037180778 10.1038/nature01321
111. Hirsch E. C., Vyas S., Hunot S., Neuroinflammation in Parkinson's disease. Parkinsonism and Related Disorders 2012 18 1 S210 S212 2-s2.0-84858667311
112. Laflamme N., Lacroix S., Rivest S., An essential role of interleukin-1 β in mediating NF- B activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. Journal of Neuroscience 1999 19 24 10923 10930 2-s2.0-0033573451
113. Blatteis C. M., Role of the OVLT in the febrile response to circulating pyrogens. Progress in Brain Research 1992 91 409 412 2-s2.0-0026667651
114. Henry C. J., Huang Y., Wynne A. M., Godbout J. P., Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1 β and anti-inflammatory IL-10 cytokines. Brain, Behavior, and Immunity 2009 23 3 309 317 2-s2.0-61349193143 10.1016/j.bbi.2008.09.002
115. Gao H.-M., Zhang F., Zhou H., Kam W., Wilson B., Hong J.-S., Neuroinflammation and α -synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environmental Health Perspectives 2011 119 6 807 814 2-s2.0-79955921784 10.1289/ehp.1003013
116. Ton T. G., Heckbert S. R., Longstreth W. T. Jr., Rossing M. A., Kukull W. A., Franklin G. M., Swanson P. D., Smith-Weller T., Checkoway H., Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Movement Disorders 2006 21 7 964 969 2-s2.0-33746894717 10.1002/mds.20856
117. Plane J. M., Shen Y., Pleasure D. E., Deng W., Prospects for minocycline neuroprotection. Archives of Neurology 2010 67 12 1442 1448 2-s2.0-78650132056 10.1001/archneurol.2010.191
118. Ravina B., A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006 66 5 664 671 2-s2.0-33645894705 10.1212/01.wnl.0000201252.57661.e1
119. Thévenet J., Pescini Gobert R., Hooft van Huijsduijnen R., Wiessner C., Sagot Y. J., Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE 2011 6 6 e21519 2-s2.0-84855737999
120. Moehle M. S., Webber P. J., Tse T., Sukar N., Standaert D. G., Desilva T. M., Cowell R. M., West A. B., LRRK2 inhibition attenuates microglial inflammatory responses. Journal of Neuroscience 2012 32 5 1602 1611 2-s2.0-84856632181 10.1523/JNEUROSCI.5601-11.2012
121. Hinkle K. M., Yue M., Behrouz B., LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Molecular Neurodegeneration 2012 7, article 25
122. Wenz T., PGC-1 α activation as a therapeutic approach in mitochondrial disease. IUBMB Life 2009 61 11 1051 1062 2-s2.0-77449139468 10.1002/iub.261
123. Hondares E., Pineda-Torra I., Iglesias R., Staels B., Villarroya F., Giralt M., PPAR δ but not PPAR α activates PGC-1 α gene transcription in muscle. Biochemical and Biophysical Research Communications 2007 354 4 1021 1027 2-s2.0-33846890004 10.1016/j.bbrc.2007.01.092
124. Pardo R., Enguix N., Lasheras J., Feliu J. E., Kralli A., Villena J. A., Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator-activated receptor γ coactivator-1 α PLoS ONE 2011 6 11 2-s2.0-80455174540 10.1371/journal.pone.0026989 e26989
125. Suwa M., Egashira T., Nakano H., Sasaki H., Kumagai S., Metformin increases the PGC-1 α protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. Journal of Applied Physiology 2006 101 6 1685 1692 2-s2.0-33845411854 10.1152/japplphysiol.00255.2006
126. Chowanadisai W., Bauerly K. A., Tchaparian E., Wong A., Cortopassi G. A., Rucker R. B., Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1 α expression. Journal of Biological Chemistry 2010 285 1 142 152 2-s2.0-73649125823 10.1074/jbc.M109.030130
127. Irrcher I., Ljubicic V., Kirwan A. F., Hood D. A., AMP-activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells. PLoS ONE 2008 3 10 e3614 2-s2.0-58349095060
128. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J., Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1 α Cell 2006 127 6 1109 1122 2-s2.0-33845399894 10.1016/j.cell.2006.11.013